Share:
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
SANTA FE, N. M., May 04, 2021 (GLOBE NEWSWIRE) Avisa Diagnostics Inc. (formerly, FogChain Corp.) (the Company ) is pleased to announce the closing of its previously announced reverse takeover transaction (the Transaction ) with Avisa Pharma Inc. ( Avisa ). In accordance with the merger agreement and plan of reorganization dated February 1, 2021 (the Merger Agreement ), which superseded and replaced the previously announced Letter of Intent dated January 12, 2021, the Transaction was effected by way of a triangular merger between the Company, Avisa, and a wholly owned, Delaware subsidiary of the Company ( Subco ) pursuant to the laws of the State of Delaware. The combined public company resulting from the Transaction (the Resulting Issuer ) will carry on the business of Avisa.
Early Warning News Release - NMSIC Focused, L L C Holdings of Avisa Diagnostics Inc benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
(CSE: FOG.X) (OTCB: FOGCF) (FRA: MUU3) (the
Company or
FogChain ) is pleased to announce, further to its news release dated January 13, 2021, the Company has entered into a merger agreement and plan of reorganization (the
Definitive Agreement ) with Avisa Pharma Inc. (
Avisa ) and FogChain USA Inc., a wholly-owned subsidiary of FogChain, dated February 1, 2021, in respect of a statutory merger under the Delaware General Corporation Law pursuant to which the Company has agreed to acquire all of the issued and outstanding shares in the capital of Avisa (the
Avisa Shares ), a privately held Delaware company, in exchange for the issuance of approximately 33,263,123 common shares and 14,825,786 restricted voting shares in the capital of the Company (the